Pasireotide

Treatment for Cushing's Syndrome

Typical Dosage: 600-900 mcg BID (injectable) or 10-40 mg IM every 28 days (LAR)

Effectiveness
25%
Safety Score
55%
Clinical Trials
5
Participants
500

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
55
DangerousModerateSafe
Treatment Details
Dosage Range
600-900 mcg BID (injectable) or 10-40 mg IM every 28 days (LAR)
Time to Effect
1-3 months
Treatment Duration
lifetime
Evidence Quality
HIGH
Number Needed to Treat (NNT)
4.5(Treat 4.5 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
1.5(Treat 1.5 patients to see 1 additional serious adverse event)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$150,000
Monitoring:$2,500
Side Effect Mgmt:$2,000
Total Annual:$154,500
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POOR
ICER
$550,000/QALY
QALYs Gained
0.4
Outcome-Based Costs
Cost per Responder
$618,000
Cost per Remission
$618,000
Pasireotide Outcomes

for Cushing's Syndrome

Efficacy Outcomes
Overall Effectiveness
+25%
Response Rate
+25%
Remission Rate
+25%
Common Side Effects
Hyperglycemia (often leading to diabetes)
+75%
Diarrhea/Nausea
+50%
Abdominal pain
+25%
Gallstones
+15%
Bradycardia
+8%

Sources:

nih.gov
england.nhs.uk
hra.nhs.uk

WARNING: LIMITED TRIALS AVAILABLE

You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!

FIX IT
Active Clinical Trials
No active trials currently recruiting for this treatment

No active trials found in ClinicalTrials.gov

Completed Clinical Trials
3 completed trials for Pasireotide in Cushing's Syndrome

A Study to Assess SOM230 in Patients With Pituitary Cushing's Disease

NCT00088608COMPLETEDPHASE2
View Study
26 participants
INTERVENTIONAL
Los Angeles, United States +4 more
Started: Apr 1, 2004

Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies

NCT01794793COMPLETEDPHASE4
View Study
337 participants
INTERVENTIONAL
La Jolla, United States +93 more
Started: Jun 10, 2013

Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease

NCT01374906COMPLETEDPHASE3
View Study
150 participants
INTERVENTIONAL
Phoenix, United States +81 more
Started: Nov 4, 2011